PubMed Health⌕ Search

Biomedical subjects

U Assogba

Publications and source records attributed to U Assogba.

28 records · Page 2Linked to original sources
PubMed1988

[Plasma exchange with very low molecular weight heparin CY 222. Biological profile and therapeutic value].

In a clinical, between-patient study we investigated the effects of a VLMW Heparin fragment (CY 222) versus standard heparin (SH) in plasma exchanges (n = 10) on coagulation factors (CF). Fibrinogen (FGN), II, V, VIIF + X, IX, XI, XII, VIIIc, VIIIRag, VIIIvwf and ATIII, ProtC, ProtS, Plasminogen (PGN), Activated Thromboplastin time (APTT), Prothrombin time (PT), Thrombin time (TT), anti factor Xa (Axa), DDimer, Platelet count. Heparin was administered as a bolus and by infusion during the session, CY 222 as a bolus dose only; 1 to 1.5 plasma volume was exchanged with substitution by 5% albumin. Results (mean, s.d.) at the end of the session (End) and 4 hours later (T4) were analyzed and showed no differences between groups (with CY 222 and with SH) for technical and clinical findings. Biologically, CF were similar in both groups except for Factor XII levels at the end of the session, and Factors II, V, XII at T4. Prolonged APTT in all samples appear related to low FGN. Significant differences in Axa activities were found for each treatment when compared with its own standard, suggesting different ranges of activities of both drugs. Changes in D-dimer levels differed during the session and four hours after the session with the drug tested, and could be related to their mode of administration. Clinical efficiency and tolerance were excellent both with CY 222 and SH.

Adult↗
PubMed1988

[HIV1 infections in dialysis centers. Prospective studies in 4 centers in Ile-de-France].

A prospective multicenter study was undertaken between february 1985 and august 1986 in 4 haemodialysis centers in the Paris area (France) in order to assess the prevalence of HIV1 infection and the risk of transmission of the virus within the centers. Every four months a follow-up was carried out in 221 patients undergoing haemodialysis (HD) and in 40 staff members caring for the patients in 2 centers. 62 patients undergoing peritoneal dialysis (PD) and 126 haemodialysis patients who transited through a center (HDT) were screened once. A questionnaire exploring risk factors was completed for each patient and staff member. Sera were tested for HIV1 antibodies by ELISA (ELAVIA) and confirmed by Western Blot. Of the 347 HD + HDT patients, 4 were found to be positive. Of the 221 HD patients, 1 multi-transfused haemophiliac and 1 multitransfused Nigerian without other risk factors were positive in the first screening. Another patient seroconverted after blood transfusion during the study; no other risk factors existed and the donor has not yet been found. One of the 126 HDT patients had received infected plasma. No staff members or PD patients were positive. Thus there is no evidence within the centers of transmission, from patient-to-patient or patient-to-staff. Although HIV1 seems to be less infectious than HBV, precautions to prevent transmission of HIV1 in dialysis centers should be maintained.

Acquired Immunodeficiency Syndrome↗
PubMed1988

[Removal of prednisone and prednisolone during plasma exchange].

Prednisone and prednisolone extraction was determined during seven sessions of plasma exchange in four patients. Each patient received 0.5 mg/kg of prednisone administered orally 2 hours before plasma exchange. Concentrations of prednisone and prednisolone were determined in blood before, every half hour during and at the end of plasma exchange. Both drugs were also determined in removed plasma, mean volume of removed plasma being 0.96 plasmatic mass. The amount of combined prednisone and prednisolone removed by plasma exchange was 1.70% of the administered prednisone dose. This quantity appears minimal and supplemental dosing of prednisone or modification of administration time would seem to be unnecessary.

Chromatography, High Pressure Liquid↗
PubMed1988

Prospective study of HIV I seropositive patients in hemodialysis centers.

A prospective multicenter study was undertaken between February 1985 and August 1986 in 4 hemodialysis centers in the Paris area (France) in order to assess the prevalence of HIV I infection and the risk of transmission of the virus within the centers. A four-month follow-up was carried out in 221 patients undergoing hemodialysis (HD) and in 40 staff members caring for the patients in 2 centers. 62 patients undergoing peritoneal dialysis (PD) and 126 hemodialysis patients who transited through a center (HDT) were screened once. A questionnaire exploring risk factors was completed for each patient and staff member. Sera were tested for HIV I antibodies by ELISA (ELAVIA) and confirmed by Western Blot. Of the 347 HD + HDT patients, 4 were found to be positive. Of the 221 HD patients, 1 multi-transfused hemophiliac and 1 multitransfused Nigerian without other risk factors were positive in the first screening. Another patient seroconverted after transfusion during the study; no other risk factors existed and the donor has not yet been found. One of the 126 HDT patients had received infected plasma. No staff members or PD patients were positive. No transmission within centers, from patient-to-patient or patient-to-staff was evidenced. Although HIV I seems to be less infectious than HBV, precautions to prevent transmission of HIV I in dialysis centers should be maintained.

Acquired Immunodeficiency Syndrome↗
PubMed1983

[Allogeneic immune response after blood transfusion in patients awaiting renal transplantation].

To investigate the mechanisms of the beneficial effect of blood transfusions (BT) on subsequent kidney transplant survival, we studied the influence of 3 planned BT on lymphocyte reactivity and on lymphocytotoxic antibody (LT) production in previously non-transfused uremic patients. A sustained and non-specific decrease in mixed lymphocyte reactivity (MLR) was observed in approximately 60% of the cases, whereas other patients had only a transient decrease but otherwise normal or even increased responses. Neither the pre-BT degree of immune responsiveness nor the clinical status of the patients had any influence on this phenomenon. Similarly, hepatitis B seroprophylaxy or vaccination did not interfere with this BT effect. Anti-HLA, LT, which are potentially harmful for the transplant, were noted in 13% of cases, while 13% additional cases displayed "cold" anti-B lymphocyte LT which do not have the same prognostic value. In some instances, suppression of cellular reactivity developed concurrently with LT production, which indicates that there is no interaction between cellular and humoral responses induced by BT.

Antibody Formation↗
PubMed1983

The influence of blood transfusions on lymphocyte reactivity in man.

The effect of planned blood transfusion (BT) on lymphocyte reactivity in previously non-transfused uraemic patients has been investigated. A sustained and non-specific decrease in MLR was observed in approximately 60 per cent of the cases. Other patients had only a transient decrease, normal or increased response. Lymphocyte suspensions whose proliferation was reduced after BT suppressed the response of autologous cells taken before BT. Neither pre-BT degree of immune responsiveness nor clinical status of the patients had any influence on this phenomenon.

Blood Grouping and Crossmatching↗
PubMed1983

Interleukin-2 production after blood transfusions in prospective kidney transplant recipients.

We have investigated whether suppression of the allogeneic response after blood transfusion (BT) could be due to inhibition of the production or activity of Interleukin-2 (IL-2), a soluble mediator involved in T lymphocyte proliferation. Reduction of IL-2 production after BT was less frequent than, but significantly associated with, non specific MLR suppression. However, MLR suppressor cells did not inhibit the release of IL-2 from autologous pre-BT lymphocytes. In addition, post-BT soluble suppressor factors of the MLR did not affect the ability of IL-2 to promote cell proliferation. Thus, although MLR suppression after BT is associated with reduced IL-2 production, this is not a major mechanism involved in this effect.

Blood Transfusion↗
PubMedDate not supplied

Hemolytic and uremic syndrome after heart transplantation.

Two cases of hemolytic and uremic syndrome in heart transplant recipients are reported. Among solid organ transplantations, this complication mainly occurred in renal transplantation and only 1 case was reported in heart transplantation in the literature. Cyclosporine was the only etiologic factor found. The renal outcome was severe with end-stage renal failure and no recovery of the renal function despite stopping cyclosporine, corticoids and plasma exchange.

Adult↗